PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Healthcare reforms in Japan PART 06: Regulatory landscape in Japan • ASRM • PMD Act PART 07: Reimbursement scenario • Reimbursement scenario for regenerative medicine in Japan PART 08: Gene therapy: An emerging field in regenerative medicine PART 09: Pipeline portfolio PART 10: Market landscape • Market overview • Five forces analysis PART 11: Market segmentation by product • Cell therapy • Cell therapy regenerative medicine market in Japan • Tissue scaffold • Tissue scaffold regenerative medicine market in Japan PART 12: Market segmentation by application • Dermatology • Musculoskeletal • Cardiovascular • Other PART 13: Market drivers • Transformation of regulatory landscape fostering quick approval of regenerative medicines • Growing partnerships of MNCs with local vendors in Japan • Recent product approvals fuel the market growth • Government initiatives driving regenerative medicine market in Japan PART 14: Impact of drivers PART 15: Market challenges • Ethical challenges involved in regenerative medicine • High cost and failure rate in clinical trials coupled with inadequate clinical evidence • Low competitive edge of Japanese regenerative medicine market over other developed nations PART 16: Impact of drivers and challenges PART 17: Market trends • Strong pipeline portfolio of regenerative medicines • Entry of new players expanding the applications of regenerative medicine • Strategic collaborations and acquisitions • Advent of 3D tissue bioprinters for the development of regenerative medicines PART 18: Vendor landscape • Competitive scenario • Key news • Product approvals • Partnerships • Mergers and acquisitions • Other PART 19: Key vendor analysis • CellSeed • JCR Pharmaceuticals • Japan Tissue Engineering (J-TEC) • Terumo • Upcoming vendors • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Regenerative medicine application in various therapeutics Exhibit 03: Major applications of regenerative medicine in Japan Exhibit 04: Regenerative medicine legislation acts in Japan Exhibit 05: Product approval and regulatory characteristics in Japan Exhibit 06: Overview of regenerative medicine regulation acts Exhibit 07: Landscape of regenerative medicine in Japan Exhibit 08: Risk categories of regenerative medical technologies Exhibit 09: Regenerative medicine approval process in Japan under the ASRM Exhibit 10: Regenerative medicine approval process in Japan under PMD Act Exhibit 11: Comparison of traditional and new product approval process under the PMD Act Exhibit 12: Conditional approvals for regenerative medical products versus regular approval for pharmaceuticals Exhibit 13: Japan’s NHI pricing methods Exhibit 14: NHI pricing calculation for TEMCELL HS Exhibit 15: NHI pricing calculation for HeartSheet A kit Exhibit 16: NHI pricing calculation for HeartSheet B kit Exhibit 17: Gene therapy research by sponsorship Exhibit 18: Regenerative medicine pipeline products in Japan Exhibit 19: Pipeline analysis of regenerative medicine in Japan 2015 Exhibit 20: Pipeline products of regenerative medicine for cell therapy in 2015 Exhibit 21: Key developments in regenerative medicine market in Japan 2015 Exhibit 22: Regenerative medicine market in Japan 2015-2020 ($ millions) Exhibit 23: Regenerative medicine market in Japan: Optimistic and pessimistic analyses 2015-2020 Exhibit 24: Optimistic and pessimistic market analysis of regenerative medicine in Japan 2015-2020 Exhibit 25: Five forces analysis Exhibit 26: Regenerative medicine market in Japan by product 2015 and 2020 Exhibit 27: Positioning of segments (by product type) in regenerative medicine market in Japan 2015 Exhibit 28: Regenerative medicine market in Japan: Lifecycle analysis by product 2015 Exhibit 29: Cell therapy overview Exhibit 30: Ethical issues involved in different cell therapy research category Exhibit 31: Stem cell research policies in Japan Exhibit 32: Key cell therapy products marketed in Japan Exhibit 33: Cell therapy regenerative medicine market in Japan 2015-2020 ($ millions) Exhibit 34: Opportunity analysis of cell therapy regenerative medicine market in Japan Exhibit 35: Collaborations for R&D of tissue scaffold Exhibit 36: Tissue scaffold regenerative medicine market in Japan 2015-2020 ($ millions) Exhibit 37: Opportunity analysis of tissue scaffold in Japan regenerative medicine market Exhibit 38: Regenerative medicine market in Japan by product type 2015-2020 ($ millions) Exhibit 39: Regenerative medicine market in Japan 2015-2020 (%) Exhibit 40: Overview of the regenerative medicine dermatology market in Japan Exhibit 41: Pipeline of regenerative medicine for dermatology Exhibit 42: Overview of musculoskeletal regenerative medicine market in Japan Exhibit 43: Overview of cardiovascular regenerative medicine market in Japan Exhibit 44: Regulatory guidelines in Japan Exhibit 45: Approval process of SAKIGAKE assignment system Exhibit 46: Partnerships of MNCs with local vendors in Japan Exhibit 47: MHLW budget on drug discovery using iPS cells ($ millions) Exhibit 48: Impact of drivers Exhibit 49: Force field analysis of regenerative medicine market in Japan Exhibit 50: Impact of drivers and challenges Exhibit 51: Regenerative medicine pipeline portfolio 2015 Exhibit 52: Current applications of regenerative medicine Exhibit 53: Future applications of regenerative medicine Exhibit 54: Major strategic collaborations and acquisitions in Japan Exhibit 55: Impact of trends in regenerative medicine in Japan 2015-2020 Exhibit 56: Presence of vendors in regenerative medicine Exhibit 57: CellSeed: Profile Exhibit 58: CellSeed: Strength analysis Exhibit 59: CellSeed: Growth strategy matrix Exhibit 60: CellSeed: Opportunity assessment Exhibit 61: JCR Pharmaceuticals: Profile Exhibit 62: JCR Pharmaceuticals: Strength analysis Exhibit 63: JCR Pharmaceuticals: Growth strategy matrix Exhibit 64: JCR Pharmaceuticals: Opportunity assessment Exhibit 65: J-TEC: Profile Exhibit 66: J-TEC: Strength analysis Exhibit 67: J-TEC: Growth strategy matrix Exhibit 68: J-TEC: Opportunity assessment Exhibit 69: Terumo: Profile Exhibit 70: Terumo: Strength analysis Exhibit 71: Terumo: Growth strategy matrix Exhibit 72: Terumo: Opportunity assessment

CellSeed, JCR Pharmaceuticals, Japan Tissue Engineering, Terumo, Astellas, Caladrius Biosciences, Healios, Fujifilm,Rohto Pharmaceuticals, FUJISOFT Tissue Engineering, MediBIC, MEDI NET, Nikon, TAKARA, CMIC, EPS, Cyfuse Biomedical, Irvine Scientific, Kaken, Regience, Sumitomo Dainippon, Takeda, Alfresa, MEDIPAL Holdings, and TOHO.